Lee J, et al. Efficacy of NAs in treatment naïve CHB

Supplementary Figure 7. Sensitivity analysis of 48-week virologic response. (A) 48-week virologic response in RCTs. (B) 48-week virologic response in compensated liver diseases. (C) 48-week virologic response in studies which used HBV DNA 20 IU/mL as a lower limit of detection. RCT, randomized controlled trial; HBV, hepatitis B virus; CI, confidence interval; ETV, entecavir; BSV, besifovir dipivoxil maleate; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide; MA, meta-analysis; NMA, network meta-analysis.